Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A small clinical trial showed that cancer drug Nilotinib may reverse late-stage Parkinson’s disease, potentially enabling participants to speak and walk again for the first time in years.

President and co-founder of The Cure Parkinson’s Trust, Tom Isaacs, has called for a close follow up of this small study to ensure that any opportunity for a breakthrough in the treatment of Parkinson’s is not missed.

Isaacs said: ‘Nilotinib is a case in point. When people with Parkinson’s volunteer for clinical trials and feel the type of marked improvements to their symptoms and wellbeing as those reported in this study, we owe it to them, and indeed everyone, to follow the results up as quickly and as rigorously as possible.”

Go Back

Share this story

Comments


Related articles


Parkinson's

Interviews

“Since being diagnosed with Parkinson’s, my world has expanded”

The latest in our monthly series profiling WPC2019 bloggers

READ MORE
Careticker

Carers' Corner

‘Engagement platform’ lets carers log their work and receive rewards

Recognising and rewarding the work of carers via mobile platform

READ MORE
MDS Summer School for Nurses

PD in Practice

Aspiring Parkinson’s nurses urged to apply for “hands-on” summer school in Portugal

A unique opportunity to bring Parkinson’s nurses together

READ MORE